|
Notification of cessation of securities - PAR
|
29 June 2023 at 5:10pm
|
|
Primary and Secondary endpoints met in MPS I Trial
|
6 June 2023 at 12:55pm
|
|
iPPS shows 3-year equivalent durability in OA Canine Study
|
1 June 2023 at 8:50am
|
|
Change of Director's Interest Notice - Fisher
|
22 May 2023 at 5:00pm
|
|
Change of Director's Interest Notice - Rennie
|
17 May 2023 at 4:55pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 April 2023 at 2:45pm
|
|
PAR Phase 2 MPS VI clinical trial completes enrolment
|
28 April 2023 at 10:20am
|
|
iPPS Demonstrates Multiple DMOAD Signals in Phase 2 Study
|
4 April 2023 at 9:55am
|
|
Trading Halt
|
31 March 2023 at 9:45am
|
|
PAR Poster Presentation to OARSI World Congress 2023
|
28 March 2023 at 8:40am
|
|
Notification of cessation of securities - PAR
|
27 March 2023 at 4:30pm
|
|
NWR Virtual Healthcare Conference Presentation
|
22 March 2023 at 9:35am
|
|
Paradigm to present at the NWR Virtual Healthcare Conference
|
21 March 2023 at 10:15am
|
|
PAR Receives European Regulatory and Ethics Approval
|
14 March 2023 at 8:40am
|
|
Change of Chief Financial Officer
|
3 March 2023 at 8:40am
|
|
Notification of cessation of securities - PAR
|
2 March 2023 at 5:50pm
|
|
Half Yearly Report and Accounts
|
27 February 2023 at 10:20am
|
|
Paradigm Increases Presence at OARSI World Congress 2023
|
2 February 2023 at 1:15pm
|
|
Application for quotation of securities - PAR
|
31 January 2023 at 6:15pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 January 2023 at 11:30am
|
|
Notice of release of escrowed securities
|
19 January 2023 at 6:35pm
|
|
Paradigm Presentation to JP Morgan Healthcare Conference
|
11 January 2023 at 7:15pm
|
|
Appendix 4G & 2022 Corporate Governance Statement
|
10 January 2023 at 4:25pm
|
|
Notification of cessation of securities - PAR
|
30 December 2022 at 10:40am
|
|
Phase 3 OA Trial to Proceed after Formal Safety Review
|
28 December 2022 at 12:35pm
|
|
Change of Director's Interest Notice - Rennie
|
22 December 2022 at 6:45pm
|
|
Change in substantial holding
|
16 December 2022 at 8:40am
|
|
PAR Receives Allowance for Key US Patent
|
12 December 2022 at 10:35am
|
|
OA Study Data Accepted for Presentation at OARSI Congress
|
8 December 2022 at 9:45am
|
|
Results of Meeting
|
29 November 2022 at 4:45pm
|
|
Paradigm AGM Presentation
|
29 November 2022 at 12:00pm
|
|
Notice of Annual General Meeting-Withdrawal of Resolutions
|
29 November 2022 at 8:50am
|
|
Application for quotation of securities - PAR
|
25 November 2022 at 2:05pm
|
|
Cancel - Application for quotation of securities - PAR
|
25 November 2022 at 12:40pm
|
|
Application for quotation of securities - PAR
|
23 November 2022 at 5:05pm
|
|
Paradigm CEO steps down & Appointment of MD
|
22 November 2022 at 9:45am
|
|
Paradigm Receives $7.4m R&D Tax Incentive Refund
|
18 November 2022 at 2:30pm
|
|
Notice of release of escrowed securities
|
14 November 2022 at 5:15pm
|
|
MPS-VI Program Accepted for Presentation at WorldSymposium
|
11 November 2022 at 9:45am
|
|
Bell Potter Virtual Healthcare Conference presentation
|
9 November 2022 at 9:35am
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
31 October 2022 at 8:20am
|
|
Notice of Annual General Meeting/Proxy Form
|
28 October 2022 at 1:35pm
|
|
Paradigm Doses First UK Participant in Phase 3 Trial
|
26 October 2022 at 10:00am
|
|
PAR Reports Successful Primary Endpoint in Phase 2 Trial
|
4 October 2022 at 9:35am
|
|
Trading Halt
|
30 September 2022 at 9:10am
|
|
Successful MPSVI Safety Review and PARA OA 008 Update
|
26 September 2022 at 9:35am
|
|
Date of AGM & Closing Date for Director Nominations
|
23 September 2022 at 5:20pm
|
|
Change in substantial holding
|
19 September 2022 at 4:05pm
|
|
Change of Director's Interest Notice
|
19 September 2022 at 4:05pm
|
|
Application for quotation of securities - PAR
|
14 September 2022 at 5:40pm
|
Paradigm Biopharmaceuticals